February 5, 2018 / 12:17 PM / 18 days ago

BRIEF-Spectrum Pharmaceuticals Announces Rolontis Met The Primary Endpoint In The Phase 3 Advance Study

Feb 5 (Reuters) - Spectrum Pharmaceuticals Inc:

* SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTIS™ (EFLAPEGRASTIM) MET THE PRIMARY ENDPOINT IN THE PHASE 3 ADVANCE STUDY

* SPECTRUM PHARMACEUTICALS INC - ADVANCE STUDY MET PRIMARY EFFICACY ENDPOINT

* SPECTRUM PHARMACEUTICALS - PLANS TO FILE BLA FOR RECOVER PHASE 3 STUDY IN Q4 THIS YEAR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below